Brief: 4D Molecular Therapeutics Interim Clinical Data From The On-Going Phase 1/2 Clinical Trial Of 4D-150 For Wet AMD To Be Released Monday, Nov. 14
10/11/2022 22:03
Nov 10 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4D MOLECULAR THERAPEUTICS INTERIM CLINICAL DATA FROM THE
ON-GOING PHASE 1/2 CLINICAL TRIAL OF 4D-150 FOR WET AMD TO BE
RELEASED MONDAY, NOVEMBER 14, 2022
* 4D MOLECULAR THERAPEUTICS INC - ALL 3 COHORTS HAVE BEEN
CLEARED
FOR SAFETY, WITH NO DOSE-LIMITING TOXICITIES (DLTS) BEING
REPORTED
Source text for Eikon: ID:nGNX9WfmTp
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings